Nicole Kirchhammer

Very excited to share our new paper, now out in @ScienceTM! science.org/doi/10.1126/sc… (1/3)

Our annual survey of the best #NBTAcademicStartups of 2022 continues with Vector BioPharma, which is developing a precision gene delivery platform that is devoid of viral genes nature.com/articles/d4158…

We are excited that our latest study on cDC1-mediated coordination of anti-cancer responses by tumor-infiltrating TCF1+stem-like CD8+ T cells, led by @PhilippaMeiser is now published OPEN ACCESS in @Cancer_Cell! cell.com/cancer-cell/fu… 🧵👇1/n

We are thrilled that our recent study lead by @BayerlFelix is out in @ImmunityCP today. We addressed the question how cDC1 dysfunction is regulated in tumors and to which extent this contributes to cancer immune evasion. It is Open Access!👇 cell.com/immunity/fullt… A short 🧵:

New #JITC article: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity bit.ly/3MJeEuk @NKirchhammer @KarenODixon @AlfredZippelius @MikaelPittet

Very excited to share our work on #resistance to PI3Kα inhibition in #BreastCancer published online today in @CellRepMed 🤩 #OpenAccess 📰 cell.com/cell-reports-m… Summary 🧵👇 1/10

So excited to see our research published in @NatureComms today 🤩 rdcu.be/c4HIx Tweetorial below🧵Thanks to all the great people involved, including on Twitter: @AlfredZippelius @NKirchhammer @priska_adm @natoli_marina @LImmunotherapy @HessLab @maryam_akrami 1/10

Will exhausted immune cells soon no longer be an issue? A research group funded by the SNSF has discovered that inactivation of a gene improves the endurance of #immunecells that tackle #cancer. sohub.io/pq18

A new @ScienceTM Viewpoint reviews recent developments in #immunotherapy for solid tumors and highlights progress in translational research and clinical practice. scim.ag/Ht

In cancer, hypersialylation can drive disease progression and immune escape through immune regulation, setting a potential target for cancer immunotherapy @michal_stanczak @DepBiomedicine @LImmunotherapy. Read our summary and interview =>ow.ly/L93K50LFXIN

Today's issue of @ScienceTM is a labor of love. This Special Issue highlights recent wins in the battle to improve #cancerimmunotherapy (cover credit to Davide Bonazzi). @dlhallberg

Our viewpoint on combination immunotherapies to overcome resistance. Together with @AlfredZippelius @NKirchhammer @MarcelTrefny and @priska_adm. Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment science.org/doi/10.1126/sc…

Excellent work by @michal_stanczak, Natalia Mantuano, @NKirchhammer and the whole Cancer Immunotherapy Lab at @DepBiomedicine. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade science.org/doi/10.1126/sc…

Congratulations to Jonas Lötscher winner or the DBM Research Prize. In his work published in Cell @CellCellPress, he and his group identified a new role of extracellular magnesium in modifying cellular immunity. Their findings might have implications in the field of immunotherapy

Please find below our new review on Siglecs in cancer together @michal_stanczak and artwork by @priska_adm #glycotime Siglec receptors as new immune checkpoints in cancer sciencedirect.com/science/articl…

Great collaboration between @AlfredZippelius Lab and Plückthun Lab @UZH_en, especially @MarcelTrefny, @natoli_marina, and @LaBiochemista, with help from @LImmunotherapy Lab, @michal_stanczak, @thommen_ds, and @JboettcherLab. (3/3)

In it, we assess the role of NK cells with tissue-resident traits in cancer immunotherapy, particularly their capacity to produce CCL5. In tumors lacking this NK cell population, resistance could be overcome by induced expression of CCL5 using tumor-targeted viral vectors. (2/3)

Very excited to share our new paper, now out in @ScienceTM! science.org/doi/10.1126/sc… (1/3)

Our lab’s website is live! 🤩 Developed by @bigreja Top banner designed by @joana_gcc Reach out if you’re interested in our research. Headed to #AACR2022, would love to talk to prospect #postdocs or #PhDstudents CancerDormancy & Immunity Lab correialab.com

📢 The #CancerDormancy_and_Immunity lab is open and hiring!! Get inspired by this window to the unknown, and join us @ChampalimaudF in sunny #Lisbon More info on the lab: fchampalimaud.org/research/group… Apply: fchampalimaud.org/offers/tech-co… fchampalimaud.org/offers/postdoc…

My lab is also offering a postdoc position! If you are interested in investigating mechanisms of anti-tumor immune responses in tumor models and patients, please reach out to us: basel-jobs.ch/job/post-docto…